DIrect Oral Anticoagulation and mechaNical Aortic Valve

Phase 4

Not yet recruiting

• Conditions: Aortic Valve Disease
• Interventions: Drug: Apixaban 5 MG Oral Tablet

• Registration Number: NCT05687448
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

DIAMOND study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with mechanical aortic valve at least 7 days after cardiac surgery.

Experimental group:

Patients treated with apixaban 5 mg twice daily (BID)

Active Comparator group:

Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)

The Primary objective is To demonstrate that antithrombotic treatment with apixaban is non-inferior to warfarin (INR target range 2.0 - 3.0) in patients with mechanical heart valve implanted in the aortic position for at least 7 days for the primary net clinical benefit endpoint of ischemic outcomes (death, myocardial infarction, stroke, systemic embolism and valve thrombosis) and bleeding (ISTH major and non-major clinically relevant bleeding).

Detailed Description

Antithrombotic management of patients with mechanical heart valves continues to be an important medical concern. Vitamin K antagonists (VKAs) are currently the only oral anticoagulants approved for mechanical prosthetic valve-implanted patients. As effective as these anticoagulants are, they have major drawbacks: narrow therapeutic window, variable dose-response in individuals, interaction with several foods and drugs. Achieved INR is frequently outside the target range and INR instability is a predictor of bleeding and late mortality in patients with mechanical heart valve prosthesis. Despite multiple studies that show that tissue valves have a limited durability, many patients sometimes even young choose this type of valve to avoid VKAs.

In randomized studies and registries, direct oral anticoagulants (DOACs) have demonstrated their superiority to reduce bleeding in patients with non-valvular atrial fibrillation compared to VKAs with similar efficacy and are recommended as first choice in the guidelines. Apixaban has demonstrated a favorable benefit-risk profile to reduce bleeding in the different indications (ranging from 25-50%). So far, DOACs are currently contra-indicated or not indicated in patients with a mechanical prosthesis. The results of a single small-sized phase II randomized trial testing an anti-IIa drug were disappointing and anti-Xa drugs have not been appropriately evaluated in patients with a mechanical prosthesis. Only small observational series suggest encouraging results with anti-Xa DOACs.

Ongoing randomized trials are conducted with DOACs compared to warfarin but the studies only include one type of mechanical aortic valve or mechanical valve in mitral position. Moreover, these studies are underpowered to completely answer the question about clinical ischemic and bleeding outcomes.

Then, there is an unmet clinical need for an alternative to VKAs, such as an anti-Xa DOAC like apixaban, as anticoagulation in patients with a mechanical aortic prosthetic valve. The purpose of this study is to determine if patients with mechanical prosthetic valve in the aortic position at least 7 days after cardiac surgery can be maintained effectively with a better safety (net clinical benefit) on apixaban compared to warfarin.

Study Timeline

• Study First Submitted: 2022-09-26
• Status Verified: 2023-01
• Study First Submitted QC: 2023-01-06
• Study First Posted: 2023-01-18
• Last Update Submitted: 2023-01-24
• Last Update Posted: 2023-01-26
• Study Start: 2023-03
• Primary Completion: 2024-11
• Study Completion: 2026-11

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 1044

Inclusion Criteria

1. Male or female ≥18 years of age
2. Prior implantation of a mechanical prosthetic bileaflet valve in the aortic position at least 7 days
3. Participants currently receiving anticoagulation and who can receive warfarin with a target INR= 2.0 to 3.0 or apixaban
4. Patients affiliated to social security
5. Patient able to give free, informed and written consent

Read More

Exclusion Criteria

1. Any cardiac surgery in the 7 days prior to enrollment

2. Mechanical valve in any position other than aortic valve.

3. Old aortic mechanical valves such as Starr-Edwards, Omniscience, Björk- Shiley or other tilting-disc valves

4. Any major bleeding in the three months (90 days) prior to enrollment.

5. Active bleeding or high risk of bleeding after cardiac surgery (i.e. hemopericardium) according to investigators

6. Need to be on dual antiplatelet therapy (aspirin >100 mg daily and a P2Y12 inhibitor, i.e. clopidogrel, ticagrelor, prasugrel).

7. Known hypersensitivity or other contraindications to apixaban (hepatic disease associated with coagulopathy and clinically relevant bleeding risk).

8. Creatinine clearance <30 mL/min (Cockcroft) or patients requiring apixaban dose reduction.

9. Known hypersensitivity or other contraindications to warfarin (severe hepatic

   insufficiency, malignant hypertension, pregnancy,breastfeeding, treatment with high dose of aspirin, miconazole, phenylbutazone or milepertuis).

10. Need of heparin or low molecular weight heparin and known hypersensitivity or other contraindications to these drugs specially heparin-induced thrombocytopenia

11. Ischemic stroke or intracranial hemorrhage within 1 month.

12. Active endocarditis at the time of screening for enrollment.

13. Women of childbearing potential without efficient contraception, pregnant or breastfeeding women.

14. Concomitant combined strong P-gp and CYP3A4 inducers or inhibitors.

15. History of non-compliance with recommended monthly INR testing

16. Participation in another interventional study

17. Active cancer or life expectancy less than 3 years

18. Persons deprived of their liberty by judicial or administrative decision

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental Group	Apixaban 5 MG Oral Tablet	Patients treated with apixaban 5 mg twice daily (BID)

Primary Outcome Measures

Name	Time	Method
Net Adverse Clinical Events (NACE)	Up to 48 months	The primary composite endpoint is a net clinical endpoint including a composite ischemic endpoint (death, myocardial infarction, stroke, systemic embolism and valve thrombosis) and bleeding (ISTH major and non-major clinically relevant bleeding)

Secondary Outcome Measures

Name	Time	Method
Bleeding	Up to 48 months	Bleeding (ISTH major and non-major clinically relevant bleeding)
Death	Up to 48 months	All cause-death
Valve thrombosis	Up to 48 months	Aortic Valve thrombosis adapted from VARC-3 definition
Echographic parameter of aortic valve	Up to 48 months	Peak velocity (m/s) during follow-up
Quality-of-life questionary	Up to 48 months	Quality of life measured with the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) scaled from 0 to 100
MACE	Up to 48 months	Ischemic endpoints (death, myocardial infarction, stroke, systemic embolism and valve thrombosis)

Trial Locations

Locations (1)

Service de Cardiologie Hôpital Lariboisière; 🇫🇷 Paris, France